The kynurenine system and immunoregulation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Andersson U, Wang HC, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang MH, Yang H, Tracey KJ (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565–570
Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL (2004) Indoleamine 2, 3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 61:67–77
Babcock TA, Carlin JM (2000) Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 12:588–594
Barry S, Clarke G, Scully P, Dinan TG (2009) Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 23:287–294
Belladonna ML, Puccetti P, Orabona C, Fallarino F, Vacca C, Volpi C, Gizzi S, Pallotta MT, Fioretti MC, Grohmann U (2007) Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation 84:S17–S20
Belladonna ML, Volpi C, Bianchi R, Vacca C, Orabona C, Pallotta MT, Boon L, Gizzi S, Fioretti MC, Grohmann U, Puccetti P (2008) Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 181:5194–5198
Belladonna ML, Orabona C, Grohmann U, Puccetti P (2009) TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol Med 15:41–49
Bettelli E, Carrier YJ, Gao WD, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector T(H)17 and regulatory T cells. Nature 441:235–238
Blobe GC, Schiemann WP, Lodish HF (2000) Mechanisms of disease: role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358
Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M (2002) Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72:237–241
Bozza S, Fallarino F, Pitzurra L, Zelante T, Montagnoli C, Bellocchio S, Mosci P, Vacca C, Puccetti P, Romani L (2005) A crucial role for tryptophan catabolism at the host/Candida albicans interface. J Immunol 174:2910–2918
Brown RR, Lee CM, Kohler PC, Hank JA, Storer BE, Sondel PM (1989) Altered tryptophan and neopterin metabolism in cancer-patients treated with recombinant interleukin-2. Cancer Res 49:4941–4944
Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N (2003) HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 81:199–252
Chaves AC, Cerávolo IP, Gomes JA, Zani CL, Romanha AJ, Gazzinelli RT (2001) IL-4 and IL-13 regulate the induction of indoleamine 2, 3-dioxygenase activity and the control of Toxoplasma gondii replication in human fibroblasts activated with IFN-gamma. Eur J Immunol 31:333–344
Chomarat P, Rybak ME, Banchereau J (1998) Interleukin-4. In: Thomson A (ed) The cytokine handbook, 3rd edn. Academic Press, New York, pp 133–174
Chon SY, Hassanain HH, Gupta SL (1996) Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2, 3-dioxygenase gene. J Biol Chem 271:17247–17252
Chung IY, Benveniste EN (1990) Tumor necrosis factor-alpha production by astrocytes—induction by lipopolysaccharide, IFN-gamma, and IL-1-beta. J Immunol 144:2999–3007
Daubener W, MacKenzie CR (1999) IFN-gamma activated indoleamine 2, 3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol 467:517–524
de Waal Malefyt, R, Moore KW (1998) Interleukin-10. In: Thomson A (ed) The cytokine handbook, 3rd edn. Academic Press, New York, pp 333–364
Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, Moretta L, Moretta A, Vitale M (2006) The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. Blood 108:4118–4125
Fallarini S, Magliulo L, Paoletti T, de Lalla C, Lombardi G (2010) Expression of functional GPR35 in human iNKT cells. Biochem Biophys Res Commun 398:420–425
Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P (2002) T cell apoptosis by tryptophan catabolism. Cell Death Differ 9:1069–1077
Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176:6752–6761
Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4(+)CD25(-) T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172:5149–5153
Fiers W (1991) Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 285:199–212
Fillit H, Ding W, Buee L, Kalman J, Altstiel L, Lawlor B, Wolfklein G (1991) Elevated circulating tumor-necrosis-factor levels in Alzheimers-disease. Neurosci Lett 129:318–320
Forrest CM, Mackay GM, Stoy N, Spiden SL, Taylor R, Stone TW, Darlington LG (2010) Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington’s disease. J Neurochem 112:112–122
Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 196:459–468
Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, Seishima M (2006) The signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2, 3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappa B pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 139:655–662
Gal EM, Sherman AD (1980) l-kynurenine—its synthesis and possible regulatory function in brain. Neurochem Res 5:223–239
Gigler G, Szenasi G, Simo A, Levay G, Harsing LG, Sas K, Vecsei L, Toldi J (2007) Neuroprotective effect of l-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol 564:116–122
Gonzalez A, Varo N, Alegre E, Diaz A, Melero I (2008) Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv Clin Chem 45:155–197
González-Hernandez A, LeMaoult J, Lopez A, Alegre E, Caumartin J, Le Rond S, Daouya M, Moreau P, Carosella ED (2005) Linking two immuno-suppressive molecules: indoleamine 2, 3 dioxygenase can modify HLA-G cell-surface expression. Biol Reprod 73:571–578
Grohmann U, Fallarino F, Puccetti P (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24:242–248
Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78:842–853
Guillemin GJ, Smythe G, Takikawa O, Brew BJ (2005) Expression of indoleamine 2, 3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49:15–23
Harber M, Sundstedt A, Wraith D (2000) The role of cytokines in immunological tolerance: potential for therapy. Exp Rev Mol Med 1–20
Harris HE, Andersson U (2004) The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34:1503–1512
Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L (2005) Kynurenine metabolism in multiple sclerosis. Acta Neurol Scand 112:93–96
Hassanain HH, Chon SY, Gupta SL (1993) Differential regulation of human indoleamine 2, 3-dioxygenase gene expression by interferons-gamma and -alpha. Analysis of the regulatory region of the gene and identification of an interferon-gamma-inducible DNA-binding factor. J Biol Chem 268:5077–5084
Hill M, Tanguy-Royer S, Royer P, Chauveau C, Asghar K, Tesson L, Lavainne F, Remy S, Brion R, Huber FX, Heslan M, Rimbert M, Berthelot L, Moffett JR, Josien R, Gregoire M, Anegon I (2007) IDO expands human CD4(+)CD25(high) regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 37:3054–3062
Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuuqerque EX (2001) The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotic expression: physiopathological implications. J Neurosci 21:7463–7473
Kaszaki J, Palasthy Z, Erczes D, Racz A, Torday C, Varga G, Vecsei L, Boros M (2008) Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs. Neurogastroenterol Motil 20:53–62
Kita T, Morrison PF, Heyes MP, Markey SP (2002) Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the l-kynurenine and quinolinic acid pools in brain. J Neurochem 82:258–268
Klivenyi P, Toldi J, Vecsei L (2004) Kynurenines in neurodegenerative disorders: therapeutic consideration. In: Vecsei L (ed) Frontiers in clinical neuroscience: neurodegeneration and neuroprotection, Adv Exp Med Biol, vol 541, Kluwer, New York, pp 169–183
Kocsis AK, Szabolcs A, Hofner P, Takács T, Farkas G, Boda K, Mándi Y (2009) Plasma concentrations of high-mobility group box protein1, soluble receptor for advanced glycation end products and circulating DNA in patients with acute pancreatitis. Pancreatology 9:383–391
Kronenberg M (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23:877–900
Kudo Y, Boyd CAR, Sargent IL, Redman CWG (2003) Decreased tryptophan catabolism by placental indoleamine 2, 3-dioxygenase in preeclampsia. Am J Obstet Gynecol 188:719–726
Kudo Y, Boyd CAR, Spyropoulou I, Redman CWG, Takikawa O, Katsuki T, Hara T, Ohama K, Sargent IL (2004) Indoleamine 2, 3-dioxygenase: distribution and function in the developing human placenta. J Reprod Immunol 61:87–98
Leonhardt RM, Lee SJ, Kavathas PB, Cresswell P (2007) Severe tryptophan starvation blocks onset of conventional persistence and reduces reactivation of Chlamydia trachomatis. Infect Immun 75:5105–5117
Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, Liu S, Tracey KJ, Lotze MT, Hackam DJ, Fink MP, Vodovotz Y, Billiar TR (2007) Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 293:R1538–R1544
Li MO, Wan YY, Sanjabi S, Robertson AKL, Flavell RA (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99–146
Lio D, Scola L, Crivello A, Bonafe M, Franceschi C, Olivieri F, Colonna-Romano G, Candore G, Caruso C (2002) Allele frequencies of +874T->a single nucleotide polymorphism at the first intron of interferon-gamma gene in a group of Italian centenarians. Exp Gerontol 37:315–319
Lögters TT, Laryea MD, Altrichter J, Sokolowski J, Cinatl J, Reipen J, Linhart W, Windolf J, Scholz M, Wild M (2009) Increased plasma kynurenine values and kynurenine-tryptophan ratios after major trauma are early indicators for the development of sepsis. Shock 32:29–34
Lopez AS, Alegre E, LeMaoult J, Carosella E, Gonzalez A (2006) Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol Immunol 43:2151–2160
Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342
Maes M, Mihaylova L, De Ruyter M, Kubera M, Bosmans E (2007) The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 28:826–831
Mazza J, Rossi A, Weinberg JM (2010) Innovatives uses of tumor necrosis factor alpha inhibitors. Dermatol Clin 28:559–575
McIlroy D, Tanguy-Royer S, Le Meur N, Guisle I, Royer PJ, Leger J, Meflah K, Gregoire M (2005) Profiling dendritic cell maturation with dedicated microarrays. J Leukoc Biol 78:794–803
Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev Immunol 4:762–774
Miller CL, Llenos IC, Cwik M, Walkup J, Weis S (2008) Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 52:1297–1303
Miura H, Ozaki N, Sawada M, Isobe K, Ohta T, Nagatsu T (2008) A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 11:198–209
Molano A, Illarionov P, Besra GS, Putterman C, Porcelli SA (2008) Modulation of invariant natural killer T cell cytokine responses by indoleamine 2, 3-dioxygenase. Immunol Lett 117:81–90
Müller N, Schwarz M (2006) Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10:131–148
Müller N, Schwarz MJ (2007) The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm Suppl 72:269–280
Müller N, Myint AM, Schwarz MJ (2011) Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Res 17:130–136
Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191–1193
Musso T, Gusella GL, Brooks A, Longo DL, Varesio L (1994) Interleukin-4 inhibits indoleamine 2, 3-dioxygenase expression in human monocytes. Blood 83:1408–1411
Myint AM, Kim YK (2003) Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 61:519–525
Nemeth H, Toldi J, Vecsei L (2005) Role of kynurenines in the central and peripherial nervous systems. Curr Neurovasc Res 2:249–260
O’Connor JC, Andre C, Wang YX, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW, Dantzer R (2009) Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus calmette-guerin. J Neurosci 29:4200–4209
Oxenkrug GF (2007) Genetic and hormonal regulation of tryptophan-kynurenine metabolism—implications for vascular cognitive Impairment, major depressive disorder, and aging. Ann NY Acad Sci 1122:35–49
Oxenkrug GF (2010) Tryptophan–kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Israel J Psychiatry 47:56–63
Oxenkrug GF (2011) Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders. J Neural Transm 118:75–85
Pemberton LA, Kerr SJ, Smythe G, Brew BJ (1997) Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res 17:589–595
Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10:209
Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV (2000) A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 61:863–866
Puccetti P, Grohmann U (2007) IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappa B activation. Nat Rev Immunol 7:817–823
Quinn K, Henriques M, Parker T, Slutsky AS, Zhang H (2008) Human neutrophil peptides: a novel potential mediator of inflammatory. Am J Physiol Heart Circ Physiol 295:1817–1824
Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH (2010) CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15:393–403
Raitala A, Pertovaara M, Karjalainen J, Oja SS, Hurme M (2005) Association of interferon-gamma +874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals. Scand J Immunol 61:387–390
Riedel M, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Moller HJ, Muller N (2007) Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res 41:3–7
Robinson CM, Hale PT, Carlin JM (2005) The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 25:20–30
Robotka H, Toldi J, Vécsei L (2008) l-kynurenine: metabolism and mechanism of neuroprotection. Future Neurol 3:169–188
RouasFreiss N, Goncalves RMB, Menier C, Dausset J, Carosella ED (1997) Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 94:11520–11525
Rubtsov YP, Rudensky AY (2007) TGF beta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 7:443–453
Sarkar SA, Wong R, Hackl SI, Moua O, Gill RG, Wiseman A, Davidson HW, Hutton JC (2007) Induction of indoleamine 2, 3-dioxygenase by interferon-gamma in human islets. Diabetes 56:72–79
Sas K, Robotka H, Toldi J, Vecsei L (2007) Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 257:221–239
Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303:1–10
Schwarcz R, Whetsell WO, Mangano RM (1983) Quinolinic acid—an endogenous metabolite that produces axon-sparing lesions in rat-brain. Science 219:316–318
Song H, Park H, Kim Y-S, Kim KD, Lee H-K, Cho D-H, Yang J-W, Hur DY (2011) l-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. Int Immunopharmacol. doi: 10.1016/j.intimp.2011.02.005
Steckel NK, Koldehoff M, Beelen DW, Elmaagacli AH (2005) Indoleamine 2, 3-dioxygenase expression in monocytes of healthy nonpregnant women after induction with human choriongonadotropine. Scand J Immunol 61:213–214
Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309–379
Stone TW (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 21:149–154
Stone TW (2001) Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Progr Neurobiol 64:185–218
Stone TW (2007) Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats. Eur J Neurosci 25:2656–2665
Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609–620
Stone TW, Perkins MN (1981) Quinolinic acid—a potent endogenous excitant at amino-acid receptors in CNS. Eur J Pharmacol 72:411–412
Sundén-Cullberg J, Norrby-Teglund A, Treutiger CJ (2006) The role of high mobility group box-1 protein in severe sepsis. Curr Opin Infect Dis 19:231–236
Swartz KJ, During MJ, Freese A, Beal MF (1990) Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 10:2965–2973
Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G (2002) Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196:447–457
Tiszlavicz Z, Németh B, Fülöp F, Vécsei L, Tápai K, Ocsovszky I, Mándi Y. (2011) Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn Schmiedebergs Arch Pharmacol. doi: 10.1007/s00210-011-0605-2
Van Gool AR, Verkerk R, Fekkes D, Bannink M, Sleijfer S, Kruit WHJ, van der Holt B, Scharpe S, Eggermont AMM, Stoter G, Hengeveld MW (2008) Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status. Psychiatry Clin Neurosci 62:597–602
Vecsei L, Beal MF (1991) Comparative behavioral and neurochemical studies with striatal kainic acid-lesioned or quinolinic acid-lesioned rats. Pharmacol Biochem Behav 39:473–478
Vecsei L, Miller J, MacGarvey U, Beal MF (1992) Kynurenine and probenecid inhibit pentylenetetrazol-induced and NMDA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res Bull 28:233–238
Wang JH, Simonavicius N, Wu XS, Swaminath G, Reagan J, Tian H, Ling L (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281:22021–22028
Wichers MC, Maes M (2004) The role of indoleamine 2, 3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 29:11–17
Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D (2003) Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 10:1581–1591
Wu L, Gabriel CL, Parekh VV, Van Kaer L (2009) Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 73:535–545
Xu H, Zhang G-X, Ciric B, Rostami A (2008) IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett 121:1–6
Yadav MC, Burudi EM, Alirezaei M, Flynn CC, Watry DD, Lanigan CM, Fox HS (2007) IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia 55:1385–1396
Yamamura T, Sakuishi K, Illes Z, Miyake S (2007) Understanding the behavior of invariant NKT cells in autoimmune diseases. J Neuroimmunol 191:8–15
Yang D, Biragyn A, Kwak LW, Oppenheim JJ (2002) Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 23:291–296
Zádori D, Klivényi P, Vámos E, Fülöp F, Toldi J, Vécsei L (2009) Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 116:1403–1409